Digital Health And Telemedicine Expansion Will Deepen Market Opportunity

Key Takeaways

• Expanding uninsured populations and rising drug prices are increasing demand for GoodRx's affordable prescription solutions and growing its user base.
  
• New pharma partnerships, digital health integrations, and targeted subscription services are boosting higher-margin, recurring, and diversified revenue streams.
  
• Reliance on third-party partners, regulatory shifts, new competitors, and evolving pharmacy models threaten GoodRx's revenue stability, user growth, pricing power, and market position.

Catalysts

About GoodRx Holdings

Offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States.

What are the underlying business or industry changes driving this perspective?

• Increased uninsured and underinsured populations due to recent cuts in Medicaid funding and rising health premiums are likely to drive more Americans to seek affordable prescription solutions, boosting GoodRx's addressable market and supporting growth in transaction revenues.
  
• Accelerating adoption of digital health and telemedicine, along with heightened consumer price sensitivity in the face of drug price inflation, positions GoodRx's platform as an increasingly vital resource, expanding its user base and raising potential for recurring revenue through digital pharmacy integrations.
  
• Substantial momentum in the company's pharma manufacturer solutions (32% YoY revenue growth, with management projecting 30%+ in 2025) reflects strong demand for direct-to-patient engagement, unlocking higher-margin revenue streams and providing meaningful upside to consolidated revenue and net margins.
  
• Launch and planned expansion of condition-specific and pharmacy subscription offerings (e.g., ED, weight loss, hair loss) utilize GoodRx's large, engaged audience, increasing customer lifetime value and generating more predictable and diversified revenue streams.
  
• Deeper integration with pharmacies (pharmacy counter initiatives, e-commerce, Community Link for independents) improves partnership durability and operational efficiency, leading to higher retention, reduced churn from external disruptions, and better margin stability over time.

GoodRx Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming GoodRx Holdings's revenue will grow by 5.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from 2.1% today to 7.0% in 3 years time.
• Analysts expect earnings to reach $65.2 million (and earnings per share of $0.22) by about August 2029, up from $16.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $115.8 million in earnings, and the most bearish expecting $46.4 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 27.8x on those 2029 earnings, down from 74.7x today. This future PE is lower than the current PE for the US Healthcare Services industry at 38.7x.
• Analysts expect the number of shares outstanding to grow by 0.5% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.05%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Structural changes in the pharmacy and PBM ecosystem, such as the Rite Aid bankruptcy and rapid network removals, have led to immediate and significant volume shocks for GoodRx, exposing its reliance on third-party partners and indicating ongoing risks to top-line revenue whenever major partners experience operational distress or make network changes.
  
• Erosion in the Integrated Savings Program (ISP), particularly due to PBM partners restructuring or deprioritizing the program, demonstrates how GoodRx's ability to drive prescription transaction volumes is increasingly subject to decisions outside its control; this can result in direct revenue loss, increased choppiness in monthly active user counts, and future gross margin compression.
  
• The pivot toward cost-plus and more bespoke pharmacy arrangements, while intended to improve retail partner economics, has led to higher prices at the point of sale, pressuring consumer demand for cash-pay scripts, which could further accelerate the shift of scripts back to funded benefits and constrain growth in GoodRx's core user base-ultimately impacting both revenue and net margins.
  
• Intensifying competition in direct-to-consumer prescription models (e.g., Amazon Pharmacy, digital-first health platforms) and the prospect of vertical integration among PBMs, health plans, and retail pharmacies pose a disintermediation threat to GoodRx, as competitors may bypass or undercut its pricing tools, shrinking market share and reducing future top line expansion.
  
• Regulatory changes increasing healthcare price transparency or implementing government-driven direct-to-consumer pricing models (e.g., Most Favored Nation pricing proposals) may "commoditize" GoodRx's offerings, eroding their pricing power and reducing their differentiation, which could shrink the addressable market and exert sustained pressure on revenues and margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $4.03 for GoodRx Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $5.0, and the most bearish reporting a price target of just $2.65.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $932.5 million, earnings will come to $65.2 million, and it would be trading on a PE ratio of 27.8x, assuming you use a discount rate of 9.1%.
• Given the current share price of $3.56, the analyst price target of $4.03 is 11.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.